Authors: Catherine A Koss, Urvi M Parikh
Long-acting PrEP (LA-PrEP) like CAB-LA shows promise for reducing HIV, but its use remains limited, especially outside the U.S., due to barriers like insurance and access. Early clinic models with multidisciplinary support have been successful, and innovative delivery methods, such as community health worker programs and telehealth, are being explored. Expanding equitable access and improving delivery systems are key to maximizing the impact of LA-PrEP.
Link: Long-acting preexposure prophylaxis: early data on roll-out in the United States
Resource Type: Evaluation
Year: 2024
Region:
Country: United States of America
Publisher May Restrict Access: Yes